Traverse Biosciences Announces Collaboration with the State University of New York Upstate Medical University
Monday, July 11, 2016
Source: Traverse BioSciences
Traverse Biosciences announced today that it will collaborate with the State University of New York Upstate Medical University (SUNY Upstate) on a $164,689 Peer Reviewed Medical Research Program (PRMRP) Discovery Award from the U.S. Department of Defense. The research, led by Gary Nieman, Associate Professor and Senior Research Scientist in the Department of Surgery, will evaluate the effectiveness of the company’s lead drug candidate, TRB-N0224, to treat acute lung injury, including acute respiratory distress syndrome (ARDS).
There are currently no FDA-approved pharmaceutical interventions for the treatment of ARDS, a rapidly progressing, life-threatening lung disorder affecting 190,000 patients in the U.S. alone, with a 40% mortality rate leading to 74,000 deaths per year. ARDS can be caused by a number of factors that directly/indirectly lead to lung injury, including pneumonia (40%), aspiration (15%) and major trauma (8%), though sepsis (22%) is the most lethal.
Mr. Joseph Scaduto, Founder and CEO of Traverse Biosciences, stated, “We are very excited to work with internationally-recognized experts in respiratory diseases from SUNY Upstate.” He added, “Their unparalleled expertise in the field of acute lung injury, in combination with this funding from the Department of Defense, will allow Traverse Biosciences to explore a new area of research, and to potentially develop our novel class of drug candidates for human therapeutic indications that address critical unmet medical needs, on and off the battlefield.”